Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01234532 · ClinicalTrials.gov registry record · Phase 2
Entinostat and Anastrozole in Treating Postmenopausal Women With TNBC That Can Be Removed by Surgery
A Phase 2 study, sponsored by University of Maryland, Baltimore.
- Terminated
- Registry status
- Phase 2
- Development phase
- 5
- Enrollment target
NCT01234532 is a Phase 2 study that was terminated before completion, run by University of Maryland, Baltimore. The registered enrollment target is 5 participants.
The verdict
NCT01234532, a Phase 2 study, was terminated before completion, sponsored by University of Maryland, Baltimore.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 5 participants
- Enrollment target
Study Summary
This phase II trial is studying how well giving entinostat and anastrozole together works in treating postmenopausal women with triple-negative breast cancer that can be removed by surgery. Entinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Estrogen can cause the growth of breast cancer cells. Hormone therapy using anastrozole may fight breast cancer by blocking the use of estrogen by the tumor cells. Giving entinostat together with anastrozole may be an effective treatment for breast cancer.
Interventions
- PROCEDURE therapeutic conventional surgery
- DRUG anastrozole
- OTHER diagnostic laboratory biomarker analysis
- DRUG entinostat
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2010-10 |
| Est. Completion | 2017-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01234532
The ClinicalTrials.gov registry entry for NCT01234532 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Maryland, Baltimore, which has 560 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which therapeutic conventional surgery is the first listed.
NCT01234532 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01234532 about?
NCT01234532 is a clinical study titled "Entinostat and Anastrozole in Treating Postmenopausal Women With TNBC That Can Be Removed by Surgery". This phase II trial is studying how well giving entinostat and anastrozole together works in treating postmenopausal women with triple-negative breast cancer that can be removed by surgery. Entinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Estrogen...
What is the current status of trial NCT01234532?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 5 participants. The study started on 2010-10. Estimated completion is 2017-05.
What interventions are being tested in trial NCT01234532?
The interventions under investigation include: therapeutic conventional surgery (PROCEDURE), anastrozole (DRUG), diagnostic laboratory biomarker analysis (OTHER), entinostat (DRUG).
Who is sponsoring clinical trial NCT01234532?
This trial is sponsored by University of Maryland, Baltimore, which has 560 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.